Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...

Covis Pharma, current maker of the preterm birth drug Makena, has withdrawn it from the market after a US Food and Drug Administration (FDA) panel deemed it ineffective. Approved more than a ...

Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary. The acquisition is aimed at improving Azurity’s medicine delivery offerings ...

WOBURN, Mass., March 14, 2025 /CNW/ -- Azurity Pharmaceuticals ("Azurity") announced today the successful completion of its acquisition of Covis Group S.à r.l. ("Covis") from existing investors.

WOBURN, Mass., March 14, 2025 /PRNewswire/ -- Azurity Pharmaceuticals ("Azurity") announced today the successful completion of its acquisition of Covis Group S.à r.l. ("Covis") from existing investors ...